288 related articles for article (PubMed ID: 21933129)
1. Expression, purification and development of neutralizing antibodies from synthetic BoNT/B LC and its application in detection of botulinum toxin serotype B.
Ponmariappan S; Jain S; Sijoria R; Tomar A; Kumar O
Protein Pept Lett; 2012 Mar; 19(3):288-98. PubMed ID: 21933129
[TBL] [Abstract][Full Text] [Related]
2. Effect of adjuvants on antibody titer of synthetic recombinant light chain of botulinum neurotoxin type B and its diagnostic potential for botulism.
Jain S; Ponmariappan S; Kumar O; Singh L
J Microbiol Biotechnol; 2011 Jul; 21(7):719-27. PubMed ID: 21791958
[TBL] [Abstract][Full Text] [Related]
3. Development of immunodetection system for botulinum neurotoxin serotype E.
Sarita R; Ponmariappan S; Sharma A; Kamboj DV; Jain AK
Indian J Med Res; 2018 Jun; 147(6):603-610. PubMed ID: 30168493
[TBL] [Abstract][Full Text] [Related]
4. In-Vivo Neutralization of Botulinum Neurotoxin Serotype E Using Rabbit Polyclonal Antibody Developed against BoNT/E Light Chain.
Rani S; Ponmariappan S; Sharma A; Kamboj DV; Jain AK
Protein Pept Lett; 2017; 24(6):495-502. PubMed ID: 28260503
[TBL] [Abstract][Full Text] [Related]
5. Development of immunodetection system for botulinum neurotoxin type B using synthetic gene based recombinant protein.
Jain S; Ponmariappan S; Kumar O
Indian J Med Res; 2011 Jul; 134(1):33-9. PubMed ID: 21808132
[TBL] [Abstract][Full Text] [Related]
6. Characterization of immune response induced against catalytic domain of botulinum neurotoxin type E.
Sonkar P; Chauhan V; Chauhan R; Saxena N; Dhaked RK
Sci Rep; 2020 Aug; 10(1):13932. PubMed ID: 32811892
[TBL] [Abstract][Full Text] [Related]
7. High level expression and immunochemical characterization of botulinum neurotoxin type F light chain.
Chauhan R; Chauhan V; Rao MK; Chaudhary D; Bhagyawant S; Dhaked RK
Protein Expr Purif; 2018 Jun; 146():51-60. PubMed ID: 29407166
[TBL] [Abstract][Full Text] [Related]
8. Expression of Hc fragment from Clostridium botulinum neurotoxin serotype B in Escherichia coli and its use as a good immunogen.
Gao YL; Gao S; Kang L; Nie C; Wang JL
Hum Vaccin; 2010 Jun; 6(6):462-6. PubMed ID: 20519939
[TBL] [Abstract][Full Text] [Related]
9. [Monoclonal antibodies to type A, B, E and F botulinum neurotoxins].
Abbasova SG; Ruddenko NV; Gorokhovatskiĭ AIu; Kapralova MV; Vinogradova ID; Vertiev IuV; Nesmeianov VA; Grishin EV
Bioorg Khim; 2011; 37(3):344-53. PubMed ID: 21899049
[TBL] [Abstract][Full Text] [Related]
10. Production and evaluation of a recombinant subunit vaccine against botulinum neurotoxin serotype B using a 293E expression system.
Yu Y; Shi D; Liu S; Gong ZW; Wang S; Sun Z
Hum Vaccin Immunother; 2015; 11(2):468-73. PubMed ID: 25483668
[TBL] [Abstract][Full Text] [Related]
11. Detection of botulinum neurotoxin serotype B at sub mouse LD(50) levels by a sandwich immunoassay and its application to toxin detection in milk.
Scotcher MC; Cheng LW; Stanker LH
PLoS One; 2010 Jun; 5(6):e11047. PubMed ID: 20548779
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of a recombinant Hc of Clostridium botulinum neurotoxin serotype F as an effective subunit vaccine.
Yu YZ; Li N; Wang RL; Zhu HQ; Wang S; Yu WY; Sun ZW
Clin Vaccine Immunol; 2008 Dec; 15(12):1819-23. PubMed ID: 18845829
[TBL] [Abstract][Full Text] [Related]
13. Universal and specific quantitative detection of botulinum neurotoxin genes.
Hill BJ; Skerry JC; Smith TJ; Arnon SS; Douek DC
BMC Microbiol; 2010 Oct; 10():267. PubMed ID: 20961439
[TBL] [Abstract][Full Text] [Related]
14. Cloning, high-level expression, single-step purification, and binding activity of His6-tagged recombinant type B botulinum neurotoxin heavy chain transmembrane and binding domain.
Zhou Y; Singh BR
Protein Expr Purif; 2004 Mar; 34(1):8-16. PubMed ID: 14766296
[TBL] [Abstract][Full Text] [Related]
15. Enhancing toxin-based vaccines against botulism.
Przedpelski A; Tepp WH; Zuverink M; Johnson EA; Pellet S; Barbieri JT
Vaccine; 2018 Feb; 36(6):827-832. PubMed ID: 29307477
[TBL] [Abstract][Full Text] [Related]
16. Production and evaluation of a recombinant chimeric vaccine against clostridium botulinum neurotoxin types C and D.
Gil LA; da Cunha CE; Moreira GM; Salvarani FM; Assis RA; Lobato FC; Mendonça M; Dellagostin OA; Conceição FR
PLoS One; 2013; 8(7):e69692. PubMed ID: 23936080
[TBL] [Abstract][Full Text] [Related]
17. Holotoxin Activity of Botulinum Neurotoxin Subtype A4 Originating from a Nontoxigenic Clostridium botulinum Expression System.
Bradshaw M; Tepp WH; Whitemarsh RC; Pellett S; Johnson EA
Appl Environ Microbiol; 2014 Dec; 80(23):7415-22. PubMed ID: 25239905
[TBL] [Abstract][Full Text] [Related]
18. Comparative study of immunological and structural properties of two recombinant vaccine candidates against botulinum neurotoxin type E.
Rostamian M; Mousavy SJ; Ebrahimi F; Ghadami SA; Sheibani N; Minaei ME; Arefpour Torabi MA
Iran Biomed J; 2012; 16(4):185-92. PubMed ID: 23183617
[TBL] [Abstract][Full Text] [Related]
19. Production of serotype C specific and serotype C/D generic monoclonal antibodies using recombinant H(C) and H(N) fragments from Clostridium botulinum neurotoxin types C(1) and D.
Curran RM; Fringuelli E; Graham D; Elliott CT
Vet Immunol Immunopathol; 2009 Jul; 130(1-2):1-10. PubMed ID: 19233482
[TBL] [Abstract][Full Text] [Related]
20. Expression and purification of neurotoxin-associated protein HA-33/A from Clostridium botulinum and evaluation of its antigenicity.
Sayadmanesh A; Ebrahimi F; Hajizade A; Rostamian M; Keshavarz H
Iran Biomed J; 2013; 17(4):165-70. PubMed ID: 23999711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
